What is the long-term trend for CorMedix's unrealized losses on investments (before tax)?

Over 2 years (2022 to 2025), CorMedix's unrealized losses on investments (before tax) has grown at a -100.0% compound annual growth rate (CAGR), from $4.14K to $0.

CorMedix CRMD Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Rigel PharmaceuticalsRIGL

$170K—

Mirum Pharmaceuticals, Inc.MIRM

——

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's unrealized losses on investments (before tax)?: CorMedix (CRMD) reported unrealized losses on investments (before tax) of $0 in Q4 2025.
What is the long-term trend for CorMedix's unrealized losses on investments (before tax)?: Over 2 years (2022 to 2025), CorMedix's unrealized losses on investments (before tax) has grown at a -100.0% compound annual growth rate (CAGR), from $4.14K to $0.